Endocyte, Inc. (ECYT) has rebounded 343.59% since its low of $1.17

Endocyte, Inc. (NASDAQ:ECYT) is on recovery track with 343.59% gain from a 1-year low price of $1.17. The company lost -9.74% to attain the price of $5.19 on Oct. 9, 2017. Throughout the recent session, the prices were hovering between $5.1 and $5.73. These shares are 34.87% off its target price of $7 and the current market capitalization stands at $236.46M. The recent change has given its price a 192.56% lead over SMA 50 and -20.76% deficit over its 52-week high. The stock witnessed 278.83% gains, 268.09% gains and 120.85% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ECYT’s volatility during a week at 18.12% and during a month it has been found around 13.22%.

Endocyte, Inc. (ECYT) Top Holders

Institutional investors currently hold around $70 million or 46% in ECYT stock. Look at its top three institutional owners. Fmr Llc owns $20.36 million in Endocyte, Inc., which represents roughly 8.61% of the company’s market cap and approximately 29.08% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 1,327,297 shares of the stock are valued at $7.63 million. The third largest holder is Pinnacle Associates Ltd, which currently holds $4.49 million worth of this stock and that ownership represents nearly 1.9% of its market capitalization.

Endocyte, Inc. 13F Filings

At the end of June reporting period, 31 institutional holders increased their position in Endocyte, Inc. (NASDAQ:ECYT) by some 3,133,479 shares, 52 decreased positions by 4,824,961 and 16 held positions by 4,300,375. That puts total institutional holdings at 12,258,815 shares, according to SEC filings. The stock grabbed 15 new institutional investments totaling 1,000,290 shares while 24 institutional investors sold out their entire positions totaling 806,245 shares.

Endocyte, Inc. (NASDAQ:ECYT) Insider Trades

Multiple company employees have indulged in significant insider trading. Endocyte, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Vice President of Research Leamon Christopher P has sold 23,244 shares of Endocyte, Inc. (ECYT) in trading session dated Dec. 30, 2016. These shares are worth $59,272 and were traded at $2.55 each. The SEC filing shows that Low Philip S performed a purchase of 11,375 shares. The Chief Science Officer added these shares by way of transaction on May. 10, 2016. The company’s shares were assimilated at $3.52 per share worth to an investment of some $40,040 on account of Low Philip S.

Director, Middleton Fred A, purchased 30,000 common shares of Endocyte, Inc. (ECYT) in the open market. In a transaction dated Jan. 19, 2016, the shares were bought at an average price of $2.8, giving away a sum of $84,000. After this purchase, 3,746,616 common shares of ECYT are directly owned by the insider, with total stake valued at $19,444,937.

In the transaction dated Mar. 03, 2015, the great number of shares disposed came courtesy the VP of Medical Affairs; Nguyen Binh disposed a total of 29,883 shares at an average price of $5.79, amounting to approximately $173,023. The insider now directly owns 28,359 shares worth $147,183.

Endocyte, Inc. (ECYT) Analyst Guide

Several analysts have released their opinion on Endocyte, Inc. (NASDAQ:ECYT), with 1 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.

Previous articleAchaogen, Inc. (AKAO) skyrockets 277.17% since hitting worst price of $3.68
Next articleAlphatec Holdings, Inc. (ATEC): A Detailed Look at its Institutional Ownership